miR-21 antagonism reprograms macrophage metabolism and abrogates chronic allograft vasculopathy.
basic (laboratory) research / science
heart (allograft) function / dysfunction
heart transplantation / cardiology
immunobiology
macrophage / monocyte biology: activation
molecular biology: micro RNA
rejection: vascular
translational research / science
Journal
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
ISSN: 1600-6143
Titre abrégé: Am J Transplant
Pays: United States
ID NLM: 100968638
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
revised:
19
02
2021
received:
29
11
2020
accepted:
09
03
2021
pubmed:
26
3
2021
medline:
21
10
2021
entrez:
25
3
2021
Statut:
ppublish
Résumé
Despite much progress in improving graft outcome during cardiac transplantation, chronic allograft vasculopathy (CAV) remains an impediment to long-term graft survival. MicroRNAs (miRNAs) emerged as regulators of the immune response. Here, we aimed to examine the miRNA network involved in CAV. miRNA profiling of heart samples obtained from a murine model of CAV and from cardiac-transplanted patients with CAV demonstrated that miR-21 was most significantly expressed and was primarily localized to macrophages. Interestingly, macrophage depletion with clodronate did not significantly prolong allograft survival in mice, while conditional deletion of miR-21 in macrophages or the use of a specific miR-21 antagomir resulted in indefinite cardiac allograft survival and abrogated CAV. The immunophenotype, secretome, ability to phagocytose, migration, and antigen presentation of macrophages were unaffected by miR-21 targeting, while macrophage metabolism was reprogrammed, with a shift toward oxidative phosphorylation in naïve macrophages and with an inhibition of glycolysis in pro-inflammatory macrophages. The aforementioned effects resulted in an increase in M2-like macrophages, which could be reverted by the addition of L-arginine. RNA-seq analysis confirmed alterations in arginase-associated pathways associated with miR-21 antagonism. In conclusion, miR-21 is overexpressed in murine and human CAV, and its targeting delays CAV onset by reprogramming macrophages metabolism.
Identifiants
pubmed: 33764625
doi: 10.1111/ajt.16581
pmc: PMC8518036
pii: S1600-6135(22)08748-2
doi:
Substances chimiques
MIRN21 microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3280-3295Subventions
Organisme : NIAID NIH HHS
ID : K24 AI116925
Pays : United States
Informations de copyright
© 2021 The Authors. American Journal of Transplantation published by Wiley Periodicals LLC on behalf of The American Society of Transplantation and the American Society of Transplant Surgeons.
Références
FEBS J. 2020 Aug;287(16):3350-3369
pubmed: 32255251
Nat Rev Immunol. 2008 Feb;8(2):120-30
pubmed: 18204468
J Heart Lung Transplant. 2007 Dec;26(12):1229-42
pubmed: 18096473
J Exp Med. 2010 Aug 2;207(8):1589-97
pubmed: 20643828
Lancet. 1996 Mar 9;347(9002):692-3
pubmed: 8596407
Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14339-44
pubmed: 20651252
Transplantation. 2005 May 15;79(9):1045-50
pubmed: 15880041
Eur J Cardiothorac Surg. 2011 Jul;40(1):e55-61
pubmed: 21450480
Circulation. 2002 Jul 30;106(5):599-605
pubmed: 12147543
J Clin Invest. 2015 Jan;125(1):141-56
pubmed: 25415439
Cardiovasc Pathol. 2014 Sep-Oct;23(5):253-60
pubmed: 24972526
Trends Cardiovasc Med. 2014 Nov;24(8):341-9
pubmed: 25258115
Am J Pathol. 2015 Oct;185(10):2596-606
pubmed: 26118749
Nat Immunol. 2010 Feb;11(2):141-7
pubmed: 19946272
Nature. 2008 Dec 18;456(7224):980-4
pubmed: 19043405
Circulation. 2013 Jan 29;127(4):463-75
pubmed: 23250993
Front Immunol. 2015 Jan 12;5:684
pubmed: 25628623
Nat Rev Drug Discov. 2017 Mar;16(3):203-222
pubmed: 28209991
Diabetes. 2013 May;62(5):1665-75
pubmed: 23315496
Transpl Immunol. 2011 May;24(4):210-5
pubmed: 21459143
Am J Transplant. 2003 Apr;3(4):381-9
pubmed: 12694059
PLoS One. 2015 Dec 23;10(12):e0145342
pubmed: 26699615
Haematologica. 2010 Nov;95(11):1814-22
pubmed: 20511666
Transplantation. 2013 Mar 27;95(6):835-41
pubmed: 23511211
Am J Pathol. 2015 Apr;185(4):927-42
pubmed: 25794704
Circulation. 2008 Feb 5;117(5):660-9
pubmed: 18212277
Nat Protoc. 2007;2(3):471-80
pubmed: 17406609
Circulation. 2018 Jan 30;137(5):488-503
pubmed: 28775077
J Heart Lung Transplant. 1992 Jan-Feb;11(1 Pt 1):9-23
pubmed: 1540617
Am J Pathol. 1991 Apr;138(4):791-8
pubmed: 2012171
Transplantation. 1973 Oct;16(4):343-50
pubmed: 4583148
Sci Transl Med. 2017 Nov 15;9(416):
pubmed: 29141886
PLoS One. 2013 Apr 04;8(4):e60391
pubmed: 23593209
Mol Ther. 2017 Jan 4;25(1):165-180
pubmed: 28129112
Diabetes. 2007 Apr;56(4):912-20
pubmed: 17287465
PLoS One. 2013;8(1):e53797
pubmed: 23326509
Sci Transl Med. 2012 Feb 15;4(121):121ra18
pubmed: 22344686
Am J Transplant. 2007 Sep;7(9):2075-81
pubmed: 17640316
J Cell Mol Med. 2009 Jan;13(1):39-53
pubmed: 19175699
Cell Rep. 2016 Oct 11;17(3):684-696
pubmed: 27732846
Am J Transplant. 2010 Apr;10(4):713-719
pubmed: 20199506
J Am Coll Cardiol. 2008 Aug 19;52(8):587-98
pubmed: 18702960
Curr Opin Organ Transplant. 2012 Feb;17(1):20-5
pubmed: 22157320
Proc Natl Acad Sci U S A. 2014 Aug 19;111(33):12145-50
pubmed: 25092331
J Clin Invest. 2019 Dec 2;129(12):5518-5536
pubmed: 31710308
Am J Transplant. 2014 Sep;14(9):2126-36
pubmed: 25307039
J Clin Invest. 2018 Aug 1;128(8):3490-3503
pubmed: 30010623
Front Immunol. 2018 Jan 18;9:22
pubmed: 29403501
J Heart Lung Transplant. 2012 Oct;31(10):1052-64
pubmed: 22975095
J Thorac Cardiovasc Surg. 2002 Apr;123(4):803-9
pubmed: 11986610
J Immunol. 2005 Mar 15;174(6):3741-8
pubmed: 15749914